Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

115.91USD
1:36pm EST
Change (% chg)

$2.97 (+2.63%)
Prev Close
$112.94
Open
$114.07
Day's High
$116.45
Day's Low
$111.79
Volume
322,525
Avg. Vol
495,426
52-wk High
$132.95
52-wk Low
$67.81

ABMD.O

Chart for ABMD.O

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Overall

Beta: 0.51
Market Cap(Mil.): $4,899.45
Shares Outstanding(Mil.): 43.38
Dividend: --
Yield (%): --

Financials

  ABMD.O Industry Sector
P/E (TTM): 117.26 55.81 30.77
EPS (TTM): 0.96 -- --
ROI: 11.38 7.05 15.23
ROE: 11.88 10.65 16.56

BRIEF-Abiomed Q2 revenue of $103 million, up 35 pct over prior year

* Abiomed announces q2 fy 2017 revenue of $103 million, up 35% over prior year

Oct 27 2016

BRIEF-Abiomed receives FDA ide approval for initiation of door to unloading prospective feasibility study

* Abiomed receives fda ide approval for initiation of door to unloading (dtu) prospective feasibility study

Oct 27 2016

BRIEF-Abiomed receives FDA IDE approval for initiation of DTU prospective feasibility study

* Receives FDA IDE approval for initiation of door to unloading (DTU) prospective feasibility study

Oct 27 2016

BRIEF-Abiomed reports Q2 FY 2017 gaap earnings per share $0.20

* Announces Q2 FY 2017 revenue of $103 million, up 35% over prior year

Oct 27 2016

BRIEF-Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare

* Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare

Sep 27 2016

BRIEF-Abiomed reports Q1 gaap earnings per share of $0.29

* Is maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20%

Jul 28 2016

Earnings vs. Estimates